Citation: Gagan Raju, Arezoo Haghshenas, Marianne Frieri, Prachi Anand. Sclerodermatous GVHD after Allogeneic Bone Marrow Transplant: a Review[J]. AIMS Cell and Tissue Engineering, 2017, 1(1): 3-11. doi: 10.3934/celltissue.2017.1.3
[1] | Cooke KR, Luznik L, Sarantopoulos S, et al. (2016) The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 23: 211-234. |
[2] | Jacobsohn DA, Kurland BF, Pidala J, et al. (2012) Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 120: 2545-2552. doi: 10.1182/blood-2012-04-424135 |
[3] | Flowers ME, Inamoto Y, Carpenter PA, et al. (2011) Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 117: 3214-3219. doi: 10.1182/blood-2010-08-302109 |
[4] | Salhotra A, Tsai N, Thomas SH, et al. (2015). Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50: 139-141. |
[5] | Tyndall A, Dazzi F (2008) Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol 21: 281-289. |
[6] | McCormick LL, Zhang Y, Tootell E, et al. (1999) Anti-TGF-β Treatment Prevents Skin and Lung Fibrosis in Murine Sclerodermatous Graft-Versus-Host Disease: A Model for Human Scleroderma. J Immunol 163: 5693-5699. |
[7] | Shulman HM, Kleiner D, Lee SJ, et al. (2006) Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report. Biol Blood Marrow Transplant 12: 31-47. |
[8] | Olivieri J, Coluzzi S, Attolico I, et al. (2011) Tirosine Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside. Sci World J 11: 1908-1931. doi: 10.1100/2011/924954 |
[9] | Osmola-Mańkowska A, Silny W (2013) Assessment of chronic sclerodermoid Graft-versus-Host Disease patients, using 20MHz high-frequency ultrasonography flowersand cutometer methods. Skin Res Technol 19: e417-e422. doi: 10.1111/j.1600-0846.2012.00659.x |
[10] | Lang KS, Recher M (2005) Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Med 11: 138-145. doi: 10.1038/nm1176 |
[11] | Brüggen M, Klein I, Greinix H, et al. (2014) Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood 123: 290-299. doi: 10.1182/blood-2013-07-514372 |
[12] | Hofmeister CC, Quinn A, Cooke KR, et al. (2004) Graft-versus-host disease of the skin: life and death on the epidermal edge. Biol Blood Marrow Transplant 10: 366-372. doi: 10.1016/j.bbmt.2004.03.003 |
[13] | Nikolic B, Lee S, Bronson RT, et al. (2000) Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 105: 1289. doi: 10.1172/JCI7894 |
[14] | Dander E, Balduzzi A, Zappa G, et al. (2009) Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 88: 1261-1272. doi: 10.1097/TP.0b013e3181bc267e |
[15] | Steinman L (2007) A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139-145. doi: 10.1038/nm1551 |
[16] | Broady R, Yu J, Chow V, et al. (2010) Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood 116: 5748-5751. doi: 10.1182/blood-2010-07-295436 |
[17] | Annacker O, Burlen-Defranoux O, Pimenta-Araujo R, et al. (2000) Regulatory CD4 T Cells Control the Size of the Peripheral Activated/Memory CD4 T Cell Compartment. Immunol 164: 3573-3580. doi: 10.4049/jimmunol.164.7.3573 |
[18] | Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. (2009). The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114: 4919-4927. doi: 10.1182/blood-2008-10-161638 |
[19] | Robson NC, Donachie AM, Mowat AM (2008) Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells. Eur J Immunol 38: 1238-1246. doi: 10.1002/eji.200737758 |
[20] | Filipovich AH, Weisdorf D, Pavletic S, et al. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11: 945-956. doi: 10.1016/j.bbmt.2005.09.004 |
[21] | Lee SJ (2010) Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res 23: 529-535. doi: 10.1016/j.beha.2010.09.016 |
[22] | Choi SW, Levine JE, Ferrara JLM (2010) Pathogenesis and Management of Graft versus Host Disease. Immunol Allergy Clin North Am 30: 75-101. doi: 10.1016/j.iac.2009.10.001 |
[23] | de Masson A, Bouaziz J, de Latour RP, et al. (2012) Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 120: 5089-5090. doi: 10.1182/blood-2012-09-453928 |
[24] | Denton CP, Merkel PA, Furst DE, et al. (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56: 323-333. doi: 10.1002/art.22289 |
[25] | Schlaak M, Schwind S, Wetzig T, et al. (2010) UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant 45: 1741-1748. doi: 10.1038/bmt.2010.230 |
[26] | Sanchez-Ortega I, Servitje O, Arnan M, et al. (2012) Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biol Blood Marrow Transplant 182: 318-323. |
[27] | Ratanatharathorn V, Carson E, Reynolds C, et al. (2000) Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133: 275-279. |
[28] | Kim SJ, Lee JW, Jung CW, et al. (2010) Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 95: 1935-1942. doi: 10.3324/haematol.2010.026104 |
[29] | Lee SJ, Flowers ME (2008) Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 134-141. |
[30] | Zhou H, Guo M, Bian C, et al. (2010) Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Sclerodermatous Chronic Graft-versus-Host Disease: Clinical Report. Biol Blood Marrow Transplant 16: 403-412. doi: 10.1016/j.bbmt.2009.11.006 |
[31] | Pène J, Chevalier S, Preisser L, et al. (2008) Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180: 7423. doi: 10.4049/jimmunol.180.11.7423 |
[32] | Drobyski WR, Pasquini M, Kovatovic K, et al. (2011) Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease. Biol Blood Marrow Transplant 17: 1862-1868. doi: 10.1016/j.bbmt.2011.07.001 |
[33] | Hori A, Kanda Y, Goyama S, et al. (2005) A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 79: 372-374. doi: 10.1097/01.TP.0000151001.64189.1D |
[34] | Distler JHW, Distler O (2010) Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 69: i48-i51. doi: 10.1136/ard.2009.120196 |